Transcode Therapeutics Inc
Transcode Therapeutics Inc (ticker: RNAZ) is a very small-cap biotechnology company with a market capitalisation of approximately $12.63 million. The firm’s name indicates an orientation towards RNA science, but public investors should rely on the company’s filings and announcements for exact details on its programmes and milestones. As a microcap biotech, it is likely to be early-stage, with limited revenues, a small shareholder base and lower trading liquidity. Such stocks can be highly volatile and sensitive to binary events (e.g., study updates, regulatory news or financing rounds). Investors should weigh potential upside against common sector risks: heavy R&D spending, frequent need for external capital, dilution risk and uncertain clinical or commercial outcomes. This summary is general educational information only and not personal advice; values can rise or fall and past performance does not guarantee future returns. Check official filings, analyst notes and consider whether a microcap biotech fits your risk tolerance and portfolio timeframe.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Transcode Therapeutics' stock, with a target price of $20, indicating strong growth potential.
Financial Health
Transcode Therapeutics is showing strong financial performance with solid cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RNAZ
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Microcap dynamics
Small market cap and low liquidity can amplify price moves; that may create opportunity but also increases risk and potential difficulty exiting positions.
Early-stage focus
If the company is development-led, progress hinges on scientific milestones and funding; successful results can re-rate a stock, while setbacks can be costly.
Do your homework
Review filings, management commentary and funding needs carefully — and remember that returns are not guaranteed and values can fall as well as rise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
